Subcutaneous Biologics Market Size Grows at 11.09% CAGR, Driven by Rising Demand for Self-Administration Therapies

The subcutaneous biologics market size is calculated at USD 2.1 billion in 2025 and is expected to reach around USD 5.37 ...
Fierce Biotech

Zenas' autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...
Clinical Trials Arena on MSN

Zenas’ bifunctional mAb scores at Phase II in relapsing MS

During the Phase II MoonStone study (NCT06564311), the bifunctional monoclonal antibody (mAb) met its primary endpoint, ...

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® ...
Cancer Therapy Advisor

Fixed-Duration Subcutaneous Mosunetuzumab Shows Durable Responses, Safety in R/R Follicular Lymphoma

A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.
FiercePharma

Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...
Cure Today

Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
FiercePharma

Argenx's subcutaneous efgartigimod matches IV sibling in phase 3, clearing path to FDA filing this year

Argenx’s subcutaneous formulation of the active ingredient in Vyvgart has hit the primary endpoint in a phase 3 trial, clearing the biotech to file for approval of a product it expects to become the ...
Medindia

How Continuous Subcutaneous EEG Is Transforming Epilepsy Care

A new trial investigates long-term remote brain monitoring to improve the detection, classification, and management of ...
MedPage Today

Subcutaneous Ocrelizumab Not Inferior to IV Infusion

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MILAN -- An ...

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...
Pharmabiz

J&J announces Tremfya, the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

J&J announces Tremfya, the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years: Phoenix Tues ...